OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE’s Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic Officer of CURE, will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT.
Davidson and Duitch will discuss a variety of topics including CURE’s patented drug delivery technology, how this technology has been used to deliver cannabinoids and other pharmaceutical and nutraceutical ingredients, and how Sera Labs’ oral and topical products serve as proof of concept and commercialization for the technology. They will also discuss Nicole Kidman becoming a recent addition to the team as Sera Labs Strategic Partner and Global Brand Ambassador and how she will help further the company’s success.
“We witnessed significant growth in 2020 due to our scientific advances and our acquisition of Sera Labs,” said Davidson. “This conference provides us with a great opportunity to offer stakeholders an in-depth explanation of what our technology is, how it is marketable in many different uses, including cannabis, and why they should be investing in our promising future.”
The Sequire Cannabis Conference is a one-day event that brings together a select group of U.S. investors and leading industry participants in the cannabis space. The event will feature video presentations from more than 15 companies, organized in five tracks for attendees.
For those who cannot attend the live presentation, a video webcast of the presentation will be available. To learn more about the 2021 Squire Cannabis Conference and register to participate, visit https://cannabis-conference.mysequire.com.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward-Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contacts
Licensing Contact:
Jonathan Berlent
Chief Business Officer
CURE Pharmaceutical
Jberlent@curepharma.com
516.660.9148
Investment Contact:
investors@curepharma.com
Gary Zwetchkenbaum
Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662
Media Contact:
Kathryn Brown
CMW Media
cure@cmwmedia.com
858.264.6600